ReviewBMC cardiovascular disorders2019
Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews.
Review in BMC cardiovascular disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Continuous Glycemia Monitoring in Perioperative Period in Patients Undergoing Total Knee or Hip Arthroplasty: a Protocol of Observational Study
Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk in Adults (30 Years and Above) in Pakistan: A Multi-Year Study Investigating Incidence, Validation, and Management Strategies
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- A dual domain systematic review and meta-analysis of risk tool accuracy to predict cardiovascular morbidity in prehypertension and diabetic morbidity in prediabetes.Frontiers in endocrinology · 2025Pooled it
- Cardiovascular disease risk communication and prevention: a meta-analysis.European heart journal · 2024Pooled it
- Pooled it
- Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis.BMC medicine · 2019Pooled it
- Trial
- AI-Assisted Cardiovascular Risk Assessment by General Practitioners in Resource-Constrained Indonesian Settings Using a Conceptual Prototype: Randomized Controlled Study.Journal of medical Internet research · 2025Trial
- Cognitive and emotional reactions to pictorial-based risk communication on subclinical atherosclerosis: a qualitative study within the VIPVIZA trial.Scandinavian journal of primary health care · 2023Trial
- Psychosocial, Mental, and Suboptimal Health Measures Are Not Affected by Provision of Abdominal Aortic Calcification Imaging Results: A 12-Week RCT.AJPM focus · 2026Article
- Guideline adherence for the management of cardiovascular disease in primary care: a scoping review.Family practice · 2026Article
- Derivation and validation of a widely accessible cardiovascular risk prediction model and derived heart age for the general UK and US populations.American journal of preventive cardiology · 2026Article
- Cardiovascular risk assessment enhanced by automated machine learning in a multi-phase study.Scientific reports · 2025Article
- The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors.Breast cancer research and treatment · 2025Article
- Framingham score adapted: a valid alternative for estimating cardiovascular risk in epidemiological studies.BMC cardiovascular disorders · 2025Article
- Exploring the Current Tools in Cardiovascular Risk Assessment in the Middle East and the Need for Region-Specific Models - A Scoping Review.Therapeutics and clinical risk management · 2025Review
- Saudi Heart Association Position Statement on Troponin use for Cardiovascular Risk Screening in Asymptomatic Populations.Journal of the Saudi Heart Association · 2025Article
- Saudi Heart Association Position Statement on Early Detection of Subclinical Atherosclerosis in Clinical Practice.Journal of the Saudi Heart Association · 2025Article
- [Beyond the plaque: immunological implications of risk factors in atherosclerosis].Archivos de cardiologia de Mexico · 2024Review
- Consumer Health Informatics to Advance Precision Prevention.Yearbook of medical informatics · 2024Review
- Which surrogate insulin resistance indices best predict coronary artery disease? A machine learning approach.Cardiovascular diabetology · 2024Article
- Cardiovascular risk among community members in three communities in the Cape Metropole of the Western Cape.African journal of primary health care & family medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur objectives were to critically appraise and summarise the current evidence for the effectiveness of using cardiovascular disease (CVD) risk scoring (total risk assessment - TRA) in routine risk assessment in primary prevention of CVD compared with standard care with regards to patients outcomes, clinical risk factor levels, medication prescribing, and adverse effects.
methodsWe carried out an overview of existing systematic reviews (SRs). Presentation of the results aligned guidelines from the PRISMA statement. The data is presented as a narrative synthesis. We searched MEDLINE (Ovid), EMBASE, CENTRAL and SCOPUS databases from January 1990 to March 2017, reviewed the reference lists of all included SRs and searched for ongoing SRs in PROSPERO database. We encompassed SRs and meta-analyses which took into account RCTs, quasi-RCTs, and observational studies investigating the effect of using CVD risk scoring. Only studies performed in a primary care setting, with adult participants free of clinical CVD were eligible. Intervention was CVD risk assessment with use of the total CVD risk scoring compared with standard care with no use of TRA .
resultsWe identified 2157 records, we then recognised and analysed 10 relevant SRs. One SR reported statistically insignificant reduction of CVD death, when using TRA, the second SR presented meta-analysis which reported no effect on fatal and non-fatal CV events compared with conventional care (5.4% vs 5.3%; RR 1.01, 95% CI 0.95 to 1.08; I
conclusionsThere is limited evidence, of low overall quality, suggesting a possible lack of effectiveness of TRA in reducing CVD events and mortality, as well as a clinically insignificant influence on individual risk factor levels. Using TRA does not cause harm to patients.
trial registrationSystematic review protocol was registered with the International PROSPERO database - registration number CRD42016046898 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.